Navigation Links
UPCI, Pitt researchers present findings of cancer studies at AACR 102nd Annual Meeting
Date:4/6/2011

Orlando, Fla. How do certain multiple myeloma treatment drugs cause complications? How does the immune system become dysfunctional due to cancer? How safe is a vaccine that could prevent development of precancerous colon polyps? Those are among the many questions that will be answered by researchers from the University of Pittsburgh Cancer Institute (UPCI) and the University of Pittsburgh School of Medicine during the American Association for Cancer Research 102nd Annual Meeting 2011, April 2 to 6, in Orlando, Fla.

UPCI and Pitt researchers will present more than 80 posters, talks and tutorials, as well as lead educational sessions and chair panel discussions during the event.

Highlights include:

ORAL PRESENTATIONS:

MONDAY, APRIL 4

EMBARGOED until 1:25 p.m. ET

Mechanisms of Complications of Multiple Myeloma Treatments
Suzanne Lentzsch, M.D., Ph.D., assistant professor of medicine and clinical director of the multiple myeloma program at UPCI, will discuss her research that shows how immunomodulatory derivatives of thalidomide (IMiDs), such as lenalidomide and pomalidomide, used in multiple myeloma treatment also affect blood cell production pathways by decreasing production of a key protein needed for blood cell specialization.

"That leads to treatment complications including a reduction in the numbers of neutrophils, a kind of white blood cell, and an increase in a protein that promotes platelet clumping that in turn increases the risk for blood clots," Dr. Lentzsch explained.

EMBARGOED until 4:15 p.m. ET

Inflammatory Mediator Drives Suppressor Cells That Cause Immune System Dysfunction in Cancer
Natasa Obermajer, Ph.D., a postdoctoral fellow, will present a project conducted in the lab of senior investigator Pawel Kalinski, M.D., Ph.D., professor of surgery and UPCI researcher, that shows a single cancer-associated inflammatory mediator called prostaglandin E2 (PGE2) drives the differentiation and stability of myeloid-derived suppressor cells that play a key role in causing immune system dysfunction and a microenvironment that allows cancer cells to thrive.

"Our findings suggest that a positive feedback loop exists between PGE2 and COX-2, which regulates PGE2 production," Dr. Kalinski said. "When we disrupted this feedback loop in suppressor cells taken from cancer patients by blocking COX-2 or PGE2 signaling receptors, we stopped the cells' ability to suppress cancer-killing immune cells. This might be a new avenue to explore for future cancer treatments."

TUESDAY, APRIL 5

EMBARGOED until 1:10 p.m. ET

Cancer Vaccines Targeting Pre-Malignant Lesions
Olivera Finn, Ph.D., professor and chair, Department of Immunology, will present her work in developing vaccines that target abnormal peptides, or small pieces of protein, that are produced during the development of certain cancers. Tumor formation might be prevented with a vaccine that generates an immune response against the cells that carry these worrisome peptides.

"Vaccines that are administered as a possible treatment after cancer has already developed have not been very effective," she noted. "But if we can help the immune system find these dangerous cells in people who are at high risk for cancer but are still healthy, we might have an intervention that could prevent many cases of disease."

With colleagues including clinical collaborator Robert E. Schoen, M.D., professor of medicine, Dr. Finn also is presenting a poster (EMBARGOED until 8 a.m., Wednesday, April 6) of preliminary findings of a colon cancer prevention vaccine that is being tested for safety at UPMC. None of the vaccine recipients who have been evaluated had significant side effects, and half of them generated an immune response to MUC1, the vaccine target and a protein that becomes aberrant during the progression of advanced colon polyps into cancer. These early findings encourage further testing in a randomized trial to assess whether the vaccine can prevent recurrence of adenomatous polyps. Abstract 5510

POSTER PRESENTATIONS:

EMBARGOED UNTIL 1 p.m. ET, MONDAY, APRIL 4

Novel Drug Protects Esophagus After Radiation Exposure
Mice that swallowed the experimental drug JP4-039 before they were exposed to upper body radiation were more likely to survive than untreated animals. Of the treated animals, 75 percent survived for 30 days after exposure compared to 30 percent of the untreated group. The findings could lead to drugs that prevent esophagitis, a typical side effect of radiation treatment for lung cancer. Abstract 2502

Seizure Drug Offers Protection from Radiation Exposure
In cell and mouse experiments, carbamazepine, a drug typically prescribed to treat mood disorders, epilepsy and trigeminal neuralgia, mitigated the impact of radiation exposure by increasing autophagy, a process in which the cell components are degraded and discarded. Abstract 2495


'/>"/>

Contact: Anita Srikameswaran
SrikamAV@upmc.edu
412-578-9193
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. Using MRI, researchers may predict which adults will develop Alzheimers
2. Researchers use zebrafish to identify new gene linked to melanoma
3. Researchers identify the metabolic signaling pathway responsible for dyslipidemia
4. Fox Chase researchers develop a screen for identifying new anticancer drug targets
5. Dangerous blood pressure increases during exercise can be blocked, UT Southwestern researchers find
6. Researchers mimic bodys own healing potential to create personalised therapies for inflammation
7. BATTLE researchers identify new biomarkers for EGFR inhibition
8. Researchers need to engage lesbian, gay, bisexual, and transginder populations in health studies
9. Researchers publish molecular disease model for melanoma
10. Researchers find possible clues to tamoxifen resistance in breast cancer patients
11. UCSF researchers identify promising new treatment for childhood leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... At Hallmark Nameplate, their commitment ... they have achieved certification to ISO 13485. This certification is another way they are ... date products and services that they need. , The ISO 13485 Certification is a ...
(Date:1/18/2017)... NJ (PRWEB) , ... January 18, 2017 , ... ... care communications company, launched a new website for its Center for Biosimilars, announced ... will include the latest developments in the field of biosimilars through thought leader ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... gum disease to enamel erosion, and those dental problems can increase the risk ... Health, many pregnant women are failing to get the dental care they need. ...
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress ... dentists to choose the best drug option for each patient. Dentists have several general ... better overall outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan wanted ...
(Date:1/17/2017)... ... , ... For breast cancer clinicians and researchers who were unable to attend ... intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual ... on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... Iowa , Jan. 18, 2017   ... that subsidiary Caretta Therapeutics plans, in the second ... Venodol, a topical roll-on intended to provide relief ... opioid and steroidal analgesics. It was developed under ... to commercialize products derived from snake venom. ...
(Date:1/18/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, announces dosing the first patient ... 2 acne rosacea study. DMT210 is a topical ... in the skin responsible for the inflammation and ... This clinical trial, DMT210-003, is a 12-week, Phase ...
(Date:1/18/2017)... Jan. 17, 2017  With an annual growth ranging from 6% to 10%, ... SEA (Jakarta International Expo, March 22-24, 2017) serves the industry by fostering the ... CPhI SEA 2017? Investment Forum ASEAN -- ... Richer conference content Enhanced business matchmaking program ... ...
Breaking Medicine Technology: